VPH2

Heart failure accounts for almost a quarter of all admissions to hospital for cardiovascular events, has a high mortality (median survival around 18 months), and places a great burden on all healthcare systems, with estimated direct costs of £905m (1350m) in the United Kingdom in 2000, 2% of total NHS expenditure.

Virtual pathological heart of the virtual physiological human (VPH2) project aims to develop a patient-specific computational modelling and simulation of the human heart to assist the cardiologist and the cardiac surgeon in defining the severity and extent of disease in patients with post-ischemic Left Ventricular Dysfunction (LVD), with or without ischemic mitral regurgitation (IMR). Specific computational methods will allow clinical decision making and planning of the optimal treatment for left ventricle-valve repair. The goal is not only to deploy a fully validated technology to partner clinical institutions, but also to develop a sustainable business model associated to it.

The associated technological aim of the project is to deliver the most advanced software application framework for the development of computer-aided medicine in cardiology and cardiac surgery available in the world, going beyond the state of the art of available models.

This goal will be achieved by integrating some of the leading Open Source software in the area of computer-aided medicine and of computational bioengineering. This framework will be used by VPH2 to realise its objectives, but also by any other future project (academic or industrial) aiming to improve or extend VPH2 objectives.

For further information, please visit:
http://www.vph2.eu

Project co-ordinator:
GMD - Gesellschaft für Medizinische Datenverarbeitung mbH

Partners:

  • Intercon Sp. Z o.o. (Poland)
  • Euro PMS ltd (United Kingdom)
  • Sorin Biomedica Cardio S.r.l. (Italy)
  • SCS S.r.l. (Italy)
  • EREYNITIKO AKADIMAIKO INSTITOUTO TECHNOLOGIAS YPOLOGISTON (Greece)
  • Westfälische Wilhelms-Universität Münster (Germany)
  • PATMOS S.r.l. (Italy)
  • Aminio AB (Sweden)
  • Ecole Polytechnique Fédérale de Lausanne (Switzerland)
  • University of Bedfordshire (United Kingdom)
  • Regione Lombardia (Italy)
  • Quality & Reliability S.A (Greece)

Timetable: from 07/2008 - to 06/2011

Total cost: € 5.180.000

EC funding: € 3.780.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Open Call HORIZON-MISS-2022-CANCER-01-04…

The overall goal of the Mission on Cancer[1] and the Europe's Beating Cancer Plan[2] includes a better quality of life for patients and their families living with, and after, cancer. Project...

Insilico Medicine Raises $60 Million in …

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with...

Researchers Use AI to Predict Cancer Ris…

An artificial intelligence (AI) tool helps doctors predict the cancer risk in lung nodules seen on CT, according to a new study published in the journal Radiology. Pulmonary nodules appear as...

KTU Researchers Investigate the Links Be…

In recent years Alzheimer's disease has been on the rise throughout the world and is rarely diagnosed at an early stage when it can still be effectively controlled. Using artificial...

Speech Analysis App Predicts Worsening H…

A voice analysis app used by heart failure patients at home recognises fluid in the lungs three weeks before an unplanned hospitalisation or escalation in outpatient drug treatment. The late...

Screening for Diabetic Retinopathy Prove…

Both telemedicine and community screening for diabetic retinopathy (DR) in rural and urban settings are cost-effective in China, and telemedicine screening programs are more cost-effective, according to a study led...

Philips' Future Health Index 2022 Report…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the publication of its Future Health Index (FHI) 2022 report: 'Healthcare hits reset: Priorities shift as...

Researchers Develop Smartphone-Powered M…

A University of Minnesota Twin Cities research team has developed a new microfluidic chip for diagnosing diseases that uses a minimal number of components and can be powered wirelessly by...

App Detecting Jaundice in Babies a Succe…

A smartphone app that identifies severe jaundice in newborn babies by scanning their eyes could be a life-saver in areas that lack access to expensive screening devices, suggests a study...

InterSystems Wins Data Driven Product of…

InterSystems, a provider of next-generation solutions for enterprise digital transformation to help customers solve the most critical data challenges, has announced it received the prestigious Data Driven Product of the...

Siemens Healthineers Introduces Symbia P…

Siemens Healthineers introduces Symbia Pro.specta™, a single-photon emission computed tomography/computed tomography (SPECT/CT) system with CE Mark and Food and Drug Administration (FDA) clearance that has advanced SPECT and CT imaging...